Biologics are essential to oncology care. As patents for older biologics begin to expire, the United States is developing an abbreviated regulatory process for the approval of similar biologics (biosimilars), which raises important considerations for the safe and appropriate incorporation of biosimilars into clinical practice for patients with cancer. The potential for biosimilars to reduce the cost of biologics, which are often high-cost components of oncology care, was the impetus behind the Biologics Price Competition and Innovation Act of 2009, a part of the 2010 Affordable Care Act. In March 2011, NCCN assembled a work group consisting of thought leaders from NCCN Member Institutions and other organizations, to provide guidance regarding the challenges health care providers and other key stakeholders face in incorporating biosimilars in health care practice. The work group identified challenges surrounding biosimilars, including health care provider knowledge, substitution practices, pharmacovigilance, naming and product tracking, coverage and reimbursement, use in off-label settings, and data requirements for approval.

  • 1.

    Patient Protection and Affordable Care Act of 2009 Pub. L. No. 111–148Title VII Subtitle A “Biologics Price Competition and Innovation Act of 2009” §70017003.

    • Search Google Scholar
    • Export Citation
  • 2.

    JelkmannW. Biosimilar epoetins and other “follow-on” biologics: update on the European experiences. Am J Hematol2010;85:771780.

  • 3.

    NiederwieserDSchmitzS. Biosimilar agents in oncology/haematology: from approval to practice. Eur J Haematol2011;86:277288.

  • 4.

    MellstedtHNiederwieserDLudwigH. The challenge of biosimilars. Ann Oncol2008;19:411419.

  • 5.

    European Medicines Agency. Questions and answers on biosimilar medicines (similar biological medicinal products). Available at: http://www.emea.europa.eu/pdfs/human/pcwp/7456206en.pdf. Accessed June 2 2011.

    • Search Google Scholar
    • Export Citation
  • 6.

    SchellenkensHMoorsE. Clinical comparability and European biosimilar regulations. Nat Biotechnol2010;28:2831.

  • 7.

    European Medicines Agency. Guideline on similar biological medicinal products containing monoclonal antibodies. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/11/WC500099361.pdf. Accessed June 23 2011.

    • Search Google Scholar
    • Export Citation
  • 8.

    World Health Organization. Guidelines on evaluation of similar biotherapeutic products (SBPs). Available at: http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf. Accessed June 23 2011.

    • Search Google Scholar
    • Export Citation
  • 9.

    RogerSD. Biosimilars: current status and future directions. Expert Opin Biol Ther2010;10:10111018.

  • 10.

    Public Health Service Act 42 USC §262 (1944). “Regulation of Biological Products.”

  • 11.

    GottliebS. Biosimilars: policy, clinical, and regulatory considerations. Am J Health Syst Pharm2008;65(14 Suppl 6):S28.

  • 12.

    U.S. Food and Drug Administration. Rituximab: product approval information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/appletter/1997/ritugen112697L.htm. Accessed May 10 2011.

    • Search Google Scholar
    • Export Citation
  • 13.

    ChesonBDLeonardJP. Monoclonal antibody therapy for B-cell non-Hodgkin’s lymphoma. N Engl J Med2008;359:613626.

  • 14.

    HudisC. Trastuzumab: mechanism of action and use in clinical practice. N Engl J Med2007;357:3951.

  • 15.

    CrawfordJAllenJArmitageJ. NCCN Clinical Practice Guidelines in Oncology: Myeloid Growth Factors. Version 12011. Available at: http://www.nccn.org/professionals/physician_gls/pdf/myeloid_growth.pdf. Accessed March 4 2011.

    • Search Google Scholar
    • Export Citation
  • 16.

    DolorescoFFominayaCSchumockGT. Projecting future drug expenditures – 2011. Am J Health Syst Pharm2011;68:921932.

  • 17.

    MalikNN. Controlling the cost of innovative cancer therapeutics. Nat Rev Clin Oncol2009;6:550552.

  • 18.

    Generic Pharmaceutical Association. Savings achieved through the use of generic pharmaceuticals 2000–2009. Available at: http://www.gphaonline.org/sites/default/files/GPhA%20Savings%20Study%20Book%20Updated%20Web%20FINAL%20Jul23%2010_0.pdf. Accessed May 12 2011.

    • Search Google Scholar
    • Export Citation
  • 19.

    Congressional Budget Office. Congressional Budget Office Cost Estimate – S. 1695 Biologics Price Competition and Innovation Act of 2007. Available at: http://www.cbo.gov/ftpdocs/94xx/doc9496/s1695.pdf. Accessed May 12 2011.

    • Search Google Scholar
    • Export Citation
  • 20.

    NowickiM. Basic facts about biosimilars. Kidney Blood Press Res2007;30:267272.

  • 21.

    KuhlmannMCovicA. The protein science of biosimilars. Nephrol Dial Transplant2006;21(Suppl 5):v4v8.

  • 22.

    CrommelinDStormGVerijkR. Shifting paradigms: biopharmaceuticals versus low molecular weight drugs. Int J Pharm2003;266:316.

  • 23.

    CrommelinDBermejoTBissigM. Pharmaceutical evaluation of biosimilars: important differences from generic low-molecular-weight pharmaceuticals. Eur J Hosp Pharm Sci2005;11:1117.

    • Search Google Scholar
    • Export Citation
  • 24.

    LevequeD. Off-label use of anticancer drugs. Lancet Oncol2008;9:11021107.

  • 25.

    Van AllenEMiyakeTGunnN. Off-label use of rituximab in a multipayer insurance system. J Oncol Pract2011;7:7679.

  • 26.

    HennessySLeonardCEPlattR. Assessing the safety and comparative effectiveness of follow-on biologics (biosimilars) in the United States. Clin Pharmacol Ther2010;87:157159.

    • Search Google Scholar
    • Export Citation
  • 27.

    DeclerckPJ. Biotherapeutics in the era of Biosimilars. Drug Safety2007;30:10871092.

  • 28.

    World Health Organization. International Nonproprietary Names. Available at: http://www.who.int/medicines/services/inn/en/. Accessed July 5 2011.

    • Search Google Scholar
    • Export Citation
  • 29.

    American Medical Association. United States Adopted Names. Available at: http://www.ama-assn.org/ama/pub/physician-resources/medical-science/united-states-adopted-names-council.page. Accessed June 23 2011.

    • Search Google Scholar
    • Export Citation
  • 30.

    American Medical Association. How to Apply for a Name. Available at: http://www.ama-assn.org/ama/pub/physician-resources/medical-science/united-states-adopted-names-council/how-to-apply-for-usan.page?Accessed July 5 2011.

    • Search Google Scholar
    • Export Citation
  • 31.

    LambertBLLinSJTanHK. Designing safe drug names. Drug Safety2005;28:495512.

  • 32.

    HoffmanJMProulxSM. Medication errors caused by confusion of drug names. Drug Safety2003;26:445452.

  • 33.

    GrayTBertchKGaltK. Guidelines for therapeutic interchange-2004. Pharmacotherapy2005;25:16661680.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 614 614 88
PDF Downloads 199 199 19
EPUB Downloads 0 0 0